News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mistral Pharma Inc. Announces its Financial Results for the Second Quarter Ended September 30, 2007


11/26/2007 4:08:37 PM

MONTREAL, QUEBEC--(Marketwire - November 23, 2007) - Mistral Pharma Inc. (TSX VENTURE: MIP) (the "Corporation", "Mistral") announces today its financial results and review of operating highlights for the second quarter and for the six-month period ended September 30, 2007. "The highlights of Mistral's second quarter were the successful pilot clinical trial of our MIST-B03 product, the signing of a method use license for our MIST-B02 product and of course, the preparation for the launch of the recently approved Instillagel® by Health Canada ", said Bertrand Bolduc, the Corporation's President & CEO. "As planned, we had a successful product launch at the beginning of November 2007 "he added.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES